Donate

Evaluating The Side Effects Of Docetaxel (Taxotere) vs Cabazitaxel (Jevtana)

Many men express great hesitation to move to chemotherapy with both docetaxel (taxotere) and cabazitaxel (Jevtana) because of the side effects which can include alopecia (hair loss), nail changes, neuropathy, and dysgeusia (a distortion of the sense of taste). A group of researchers hypothesized that the adverse side effects (AE) of these two chemotherapy drugs, [...]

Is Cabazitaxel Before Docetaxel The Future Way To Go? *

Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT.  However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

Commonly Used FDA Approved Treatments for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels

Increasing Cost of Treating Men with Advanced Prostate Cancer & Its Effects on the Payers

The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]

Some Great News For Our European Brothers In Their Fight Against Advanced Prostate Cancer

Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US which are not available to them. The good news is that Sanofi has just launched Jevtana (cabazitaxel) in the UK [...]

Combining and Sequencing the New Prostate Cancer Drugs, Can It Improve Treatment Outcomes? – On the Horizon

There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]

New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

One Man’s Experience Fighting The Side Effects of Jevtana (Cabaziltaxel)

A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]

The FDA Approves Jevtana (Cabazitaxe) For Use After Chemotherapy Failure

Hot off the press- The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis SA's new chemotherapy drug for advanced prostate cancer. The drug, Jevtana (cabazitaxe) extended by nearly 2-1/2 months the lives of men with prostate cancer tumors that resist standard treatment with hormones as well as chemotherapy. The drug will be used after [...]

Go to Top